×
Hypermarcas Total Long Term Liabilities 2010-2024 | HYPMY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Hypermarcas total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
Hypermarcas Total Long Term Liabilities 2010-2024 | HYPMY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Hypermarcas total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$79.9B
Zoetis (ZTS)
$70.1B
Daiichi Sankyo, - (DSNKY)
$43.9B
Takeda Pharmaceutical (TAK)
$43.7B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$18.3B
Astellas Pharma (ALPMY)
$17.4B
United Therapeutics (UTHR)
$17B
Summit Therapeutics (SMMT)
$15.9B
Shionogi (SGIOY)
$12.3B
Neurocrine Biosciences (NBIX)
$11.4B
Corcept Therapeutics (CORT)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.5B
Orion OYJ (ORINY)
$7.4B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Stevanato Group S.p.A (STVN)
$6.2B
Grifols, S.A (GRFS)
$5.1B
Ionis Pharmaceuticals (IONS)
$5B
Ono Pharmaceutical (OPHLF)
$4.7B
Recursion Pharmaceuticals (RXRX)
$4.2B
Crinetics Pharmaceuticals (CRNX)
$3.4B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.1B
Soleno Therapeutics (SLNO)
$2B
BioCryst Pharmaceuticals (BCRX)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.8B
Evotec AG (EVO)
$1.6B
Ardelyx (ARDX)
$1.5B
Indivior (INDV)
$1.5B